Table 1.
Baseline characteristics and propensity score matched baseline characteristics
| Baseline |
Propensity score matched baseline |
|||||||
|---|---|---|---|---|---|---|---|---|
| Continuation group (n = 73) | Discontinuation group (n = 57) | p | Continuation group (n = 53) | Discontinuation group (n = 53) | p | ASD (%) | ||
| Age (years) | 70.9 ± 9.2 | 73.1 ± 9.2 | 0.188 | 72.3 ± 8.9 | 72.5 ± 9.1 | 0.88 | 3 | |
| Male | 44 (60.3%) | 31 (46.3%) | 0.097 | 58 | 29 (54.7%) | 1 | 0 | |
| Smoking habit | 12 (16.4%) | 5 (7.5%) | 0.172 | 10 | 5 (9.4%) | 1 | 0 | |
| Alcohol intake | 12 (16.4%) | 11 (16.4%) | 0.997 | 18 | 10 (18.9%) | 0.609 | 10.1 | |
| Lowest Hb level (g/dl) | 8.1 ± 2.5 | 7.5 ± 2.3 | 0.16 | 7.8 ± 2.3 | 7.7 ± 2.3 | 0.621 | 9.7 | |
| Concomitant agent | ||||||||
| NSAIDs | 12 (16.4%) | 11 (16.4%) | 0.997 | 16 | 8 (15.1%) | 1 | 0 | |
| PPI | 34 (46.6%) | 31 (46.3%) | 0.971 | 56 | 28 (52.8%) | 1 | 0 | |
| H2RA | 19 (26.0%) | 6 (9.0%) | 0.016 | 12 | 6 (11.3%) | 1 | 0 | |
| Corticosteroid | 2 (2.7%) | 4 (5.9%) | 0.6 | 4 | 2 (3.8%) | 1 | 0 | |
| Prostaglandin E1 analogue | 4 (5.5%) | 0 (0.0%) | 0.151 | 0 | 0 (0.0%) | 1 | 0 | |
| CCI | 1.82 ± 1.49 | 1.63 ± 1.49 | 0.476 | 1.64 ± 1.52 | 1.55 ± 1.48 | 0.529 | 12.4 | |
| Anticoagulant agent | 32 (43.8%) | 19 (33.3%) | 0.223 | 14 (26.4%) | 19 (35.8%) | 0.327 | 19.2 | |
| Warfarin | 30 (41.1%) | 18 (31.6%) | 0.265 | 14 (26.4%) | 19 (35.8%) | 0.327 | 19.2 | |
| DOACs | 2 (2.7%) | 1 (1.8%) | 1 | 0 (0.0%) | 0 (0.0%) | 1 | 0 | |
| Antiplatelet agent | 59 (80.8%) | 47 (82.5%) | 0.812 | 43 (81.1%) | 43 (81.1%) | 1 | 0 | |
| Low-dose aspirin | 54 (74.0%) | 40 (70.2%) | 0.631 | 39 (73.6%) | 38 (71.7%) | 0.83 | 4.2 | |
| P2Y12 receptor inhibitors | 20 (27.4%) | 11 (19.3%) | 0.282 | 12 (22.6%) | 11 (20.8%) | 0.816 | 4.6 | |
| Cilostazol | 4 (5.5%) | 3 (5.3%) | 1 | 3 (5.7%) | 3 (5.7%) | 1 | 0 | |
| Duration of discontinuation (days) | ||||||||
| 1–2 | 11 (19.3%) | 10 (18.9%) | ||||||
| 3–6 | 8 (14.0%) | 7 (13.2%) | ||||||
| ≥7 | 38 (66.7%) | 36 (67.9%) | ||||||
ASD, Absolute standardized difference; Hb, hemoblobin; NSAID, nonsteroidal anti-inflammatory drug; PPI, proton pump inhibitors; H2RA, histamine-2-receptor antagonist; CCI. Charlson comorbidity index; DOAC, direct oral anticoagulant.